TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2974874

Group type: EXPERIMENTAL
Intervention: High speed and density condition (75% correct threshold of 0.66 degrees)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: General condition (75% correct threshold of 1.2 degrees)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Displays of 63-10 dots
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Displays of only 2 dots
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Speed effect
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Angle of approach to the surface
Number of subjects: 0
Study: 31907625

Group type: EXPERIMENTAL
Intervention: Triclosan toothpaste
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo toothpaste
Number of subjects: 30
Study: 30575490

Group type: EXPERIMENTAL
Intervention: Modified FOLFIRINOX regimen (oxaliplatin 85 mg/m², irinotecan 180 mg/m², leucovorin 400 mg/m², fluorouracil 2400 mg/m² every 2 weeks for 24 weeks)
Number of subjects: 493

Group type: COMPARATOR
Intervention: Gemcitabine (1000 mg/m² on days 1, 8, and 15 every 4 weeks for 24 weeks)
Number of subjects: 493
Study: 27056608

Group type: EXPERIMENTAL
Intervention: Intravenous ketamine (0.5 mg/kg of body weight), administered over 40 minutes, twice weekly for up to 4 weeks
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Intravenous ketamine (0.5 mg/kg of body weight), administered over 40 minutes, thrice weekly for up to 4 weeks
Number of subjects: 68

Group type: COMPARATOR
Intervention: Intravenous placebo, administered over 40 minutes, twice weekly for up to 4 weeks
Number of subjects: 68

Group type: COMPARATOR
Intervention: Intravenous placebo, administered over 40 minutes, thrice weekly for up to 4 weeks
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Open-label ketamine (0.5 mg/kg of body weight), twice weekly
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Open-label ketamine (0.5 mg/kg of body weight), thrice weekly
Number of subjects: 68
Study: 24039238

Group type: EXPERIMENTAL
Intervention: Conventional pulmonary rehabilitation (CPR)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High frequency chest wall oscillation (HFCWO)
Number of subjects: 0
Study: 23157084

Group type: EXPERIMENTAL
Intervention: Supreme Laryngeal Mask Airway (SLMA)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Proseal Laryngeal Mask Airway (PLMA)
Number of subjects: 100
Study: 20483152

Group type: EXPERIMENTAL
Intervention: High dose chemotherapy
Number of subjects: 35
Study: 18762639

Group type: EXPERIMENTAL
Intervention: Operative treatment for upper lumbar herniations (L2-L3 or L3-L4)
Number of subjects: 1190

Group type: EXPERIMENTAL
Intervention: Operative treatment for L5-S1 herniations
Number of subjects: 1190

Group type: EXPERIMENTAL
Intervention: Operative treatment for L4-L5 herniations
Number of subjects: 1190
Study: 15939209

Group type: EXPERIMENTAL
Intervention: Reduction in blood lead levels from 26.3 (SD=12.0) to 8.3 (SD=6.9) microg/dL over 4 years
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Neurobehavioral Evaluation System 2 (C‐NES II) assessments
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Standardized questionnaire for chronic symptoms
Number of subjects: 27
Study: 12632413

Group type: EXPERIMENTAL
Intervention: Leflunomide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Methotrexate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patient Only index
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All Core Data Set index
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Assessor Only index
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Assessor + ESR index
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patient + ESR index
Number of subjects: 0
Study: 10535720

Group type: EXPERIMENTAL
Intervention: Imidapril (5 mg daily for 3 to 6 months)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Control group (no imidapril)
Number of subjects: 126
Study: 8767243

Group type: EXPERIMENTAL
Intervention: MAP maintained between 55 and 65 mmHg (Group 1)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: MAP maintained above 70 mmHg using norepinephrine infusion (Group 2)
Number of subjects: 27
Study: 1866527

Group type: EXPERIMENTAL
Intervention: Triazolam
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 6625217

Group type: EXPERIMENTAL
Intervention: isoflurane (I)
Number of subjects: 148

Group type: COMPARATOR
Intervention: halothane (H)
Number of subjects: 148
Study: 31657166

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Sham Electroacupuncture (sham EA)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Epidural Block (EB)
Number of subjects: 104
Study: 30356854

Group type: EXPERIMENTAL
Intervention: Assessment by radiologist, chiropractor, and second-year resident of rheumatology
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Present classifications for cervical degenerative findings
Number of subjects: 50
Study: 26848137

Group type: EXPERIMENTAL
Intervention: 100-300 mg volanesorsen
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 24293339

Group type: EXPERIMENTAL
Intervention: Pharmaceutical care (n = 315)
Number of subjects: 630

Group type: COMPARATOR
Intervention: Control group (n = 315)
Number of subjects: 630
Study: 23072556

Group type: EXPERIMENTAL
Intervention: Eye muscle surgery
Number of subjects: 144

Group type: COMPARATOR
Intervention: Active monitoring
Number of subjects: 144
Study: 19727551

Group type: EXPERIMENTAL
Intervention: Mesh hernioplasty (Group II)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Conventional fascial repair (Group I)
Number of subjects: 80
Study: 16947035

Group type: EXPERIMENTAL
Intervention: Patient evaluation of information
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Patient evaluation of their physician's decision policy
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Patient evaluation of treatment success
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Patient age
Number of subjects: 90
Study: 15733984

Group type: EXPERIMENTAL
Intervention: Trial lenses
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Contact lenses
Number of subjects: 150

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 150
Study: 11463600

Group type: EXPERIMENTAL
Intervention: Low-dose theophylline (250 mg twice per day)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 9875685

Group type: EXPERIMENTAL
Intervention: Once-daily tobramycin (4 mg/kg/day)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Twice-daily tobramycin (4 mg/kg/day)
Number of subjects: 43
Study: 7742607

Group type: EXPERIMENTAL
Intervention: Higher dose rate brachytherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lower dose rate brachytherapy
Number of subjects: 0
Study: 2607521

Group type: EXPERIMENTAL
Intervention: Felodipine
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 4574641

Group type: EXPERIMENTAL
Intervention: Nalidixic acid
Number of subjects: 36

Group type: COMPARATOR
Intervention: Ampicillin
Number of subjects: 36
Study: 30855722

Group type: EXPERIMENTAL
Intervention: Remifentanil 0.15 mcg/kg/min
Number of subjects: 50

Group type: COMPARATOR
Intervention: Remifentanil 0.3 mcg/kg/min
Number of subjects: 50
Study: 28904310

Group type: EXPERIMENTAL
Intervention: Botulinum toxin (BTX) type A injections
Number of subjects: 11

Group type: COMPARATOR
Intervention: Conservative therapy (control group)
Number of subjects: 11
Study: 26531275

Group type: EXPERIMENTAL
Intervention: General Anesthesia (GA)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Spinal Anesthesia (SA)
Number of subjects: 50
Study: 23358983

Group type: EXPERIMENTAL
Intervention: Moxifloxacin (400 mg once daily)
Number of subjects: 333

Group type: COMPARATOR
Intervention: Ciprofloxacin (750 mg twice daily) plus Amoxicillin/Clavulanic acid (1,000 mg twice daily)
Number of subjects: 333

Group type: COMPARATOR
Intervention: Both arms (Moxifloxacin and Combination Therapy)
Number of subjects: 333

Group type: COMPARATOR
Intervention: Both arms
Number of subjects: 333
Study: 21538382

Group type: COMPARATOR
Intervention: Trimetazidine (TMZ) monotherapy
Number of subjects: 11
Study: 19135286

Group type: EXPERIMENTAL
Intervention: Cholera vaccine coverage in the neighborhood
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo incidence
Number of subjects: 0
Study: 17587254

Group type: EXPERIMENTAL
Intervention: Weekly injected subcutaneous interferon (IFN)‐beta‐1a 22 microg
Number of subjects: 28
Study: 15822545

Group type: EXPERIMENTAL
Intervention: Constraint-induced movement therapy (CIMT), 6 hours daily training for 2 weeks
Number of subjects: 69

Group type: COMPARATOR
Intervention: Conservative treatment, bimanual-upper-extremity training for 2 weeks
Number of subjects: 69
Study: 10896237

Group type: EXPERIMENTAL
Intervention: Computer generated induction system (DAWN AC INDUCTION)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Manual dosing using a locally defined algorithm
Number of subjects: 101
Study: 9462992

Group type: EXPERIMENTAL
Intervention: Tiagabine (TGB)
Number of subjects: 0
Study: 8238153

Group type: EXPERIMENTAL
Intervention: Active management of labor
Number of subjects: 700

Group type: COMPARATOR
Intervention: Traditional labor management
Number of subjects: 700
Study: 4028632

Group type: EXPERIMENTAL
Intervention: Oral activated charcoal (180 gm) in divided doses over 24 hours
Number of subjects: 4

Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 4
Study: 27499018

Group type: EXPERIMENTAL
Intervention: Taliglucerase alfa 30U/kg
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Taliglucerase alfa 60U/kg
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Taliglucerase alfa dose adjusted
Number of subjects: 19
Study: 28132725

Group type: EXPERIMENTAL
Intervention: Vitamin D and leucine-enriched whey protein medical nutrition drink for 13 weeks
Number of subjects: 380

Group type: EXPERIMENTAL
Intervention: Higher baseline 25(OH)D concentrations and dietary protein intake
Number of subjects: 380

Group type: COMPARATOR
Intervention: Lower 25(OH)D concentrations
Number of subjects: 380

Group type: COMPARATOR
Intervention: Lower protein intake (g/kg/day)
Number of subjects: 380

Group type: EXPERIMENTAL
Intervention: Baseline 25(OH)D status or protein intake
Number of subjects: 380
Study: 26687836

Group type: EXPERIMENTAL
Intervention: Standard-dose imatinib
Number of subjects: 434

Group type: EXPERIMENTAL
Intervention: KIT exon 11 mutations at codons 557-558
Number of subjects: 434
Study: 26466440

Group type: EXPERIMENTAL
Intervention: CEREC crowns produced using CAD-CAM technology
Number of subjects: 10

Group type: COMPARATOR
Intervention: Ceramo-Metal Crowns produced using a conventional procedure
Number of subjects: 10
Study: 23075030

Group type: EXPERIMENTAL
Intervention: Daily breakfast consumption
Number of subjects: 1814

Group type: COMPARATOR
Intervention: Breakfast consumption frequency
Number of subjects: 1814
Study: 20635775

Group type: EXPERIMENTAL
Intervention: Prolonged Exposure (PE) therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 0
Study: 17452544

Group type: EXPERIMENTAL
Intervention: Coronary angiography post-AMI
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Statin therapy post-AMI
Number of subjects: 0
Study: 15177813

Group type: EXPERIMENTAL
Intervention: Binaural listening condition
Number of subjects: 40

Group type: COMPARATOR
Intervention: Left ear only listening condition
Number of subjects: 40

Group type: COMPARATOR
Intervention: Right ear only listening condition
Number of subjects: 40
Study: 14764998

Group type: EXPERIMENTAL
Intervention: Patients with AD
Number of subjects: 48

Group type: COMPARATOR
Intervention: Older adults
Number of subjects: 48
Study: 10574598

Group type: EXPERIMENTAL
Intervention: Patients with HP infection
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Non-HP-infected patient group
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Overall patient group
Number of subjects: 150
Study: 8665034

Group type: EXPERIMENTAL
Intervention: FK224 (4 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 10
Study: 2062984

Group type: EXPERIMENTAL
Intervention: d-amphetamine 30 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: d-amphetamine (3.75, 7.5, 15 and 30 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: methylphenidate (7.5, 15, 30 and 60 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: diazepam (5, 10, 20 and 40 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: d-amphetamine and methylphenidate
Number of subjects: 8
Study: 6135526

Group type: EXPERIMENTAL
Intervention: RX781094 (0.2 microgram/kg intravenously)
Number of subjects: 0
Study: 3964335

Group type: EXPERIMENTAL
Intervention: 20 mg N-butylscopolaminium bromide (Buscopan)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 40 mg N-butylscopolaminium bromide (Buscopan)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: N-butylscopolaminium bromide (Buscopan)
Number of subjects: 12
Study: 30098403

Group type: EXPERIMENTAL
Intervention: Cod with mashed potatoes (high GI carbohydrate)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Cod with wholegrain pasta (low GI carbohydrate)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Veal with mashed potatoes (high GI carbohydrate)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Veal with wholegrain pasta (low GI carbohydrate)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Meals with high GI carbohydrates
Number of subjects: 23

Group type: COMPARATOR
Intervention: Meals with low GI carbohydrates
Number of subjects: 23
Study: 27809891

Group type: EXPERIMENTAL
Intervention: Chondroitin sulfate 1200 mg/day
Number of subjects: 138

Group type: COMPARATOR
Intervention: Celecoxib 200 mg/day
Number of subjects: 138
Study: 25616100

Group type: EXPERIMENTAL
Intervention: Pharmacogenomic-guided warfarin treatment
Number of subjects: 100

Group type: COMPARATOR
Intervention: Non-PGx therapy (control)
Number of subjects: 100
Study: 23143737

Group type: EXPERIMENTAL
Intervention: Prone positioning
Number of subjects: 101

Group type: COMPARATOR
Intervention: Standard, left-lateral positioning
Number of subjects: 101
Study: 20518168

Group type: EXPERIMENTAL
Intervention: Plum-blossom needle on Governor Vessel and point Jiaji (EX-B 2) with routine rehabilitation method
Number of subjects: 60

Group type: COMPARATOR
Intervention: Routine rehabilitation method (Bobath + Tuina + scalp acupuncture)
Number of subjects: 60
Study: 18381308

Group type: EXPERIMENTAL
Intervention: Intra-articular lidocaine block
Number of subjects: 42

Group type: COMPARATOR
Intervention: Conscious sedation
Number of subjects: 42
Study: 16884581

Group type: EXPERIMENTAL
Intervention: Interactive Web-based intervention plus information
Number of subjects: 0

Group type: COMPARATOR
Intervention: Information website only (Control)
Number of subjects: 0
Study: 14550694

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents
Number of subjects: 352

Group type: COMPARATOR
Intervention: Bare-metal stents (control)
Number of subjects: 352
Study: 11012478

Group type: EXPERIMENTAL
Intervention: Ranitidine bismuth citrate 400 mg b.d. on days 1-5, plus amoxycillin 1 g b.d., clarithromycin 500 mg b.d. and metronidazole 500 mg b.d. on days 3-5 (RACM)
Number of subjects: 221

Group type: COMPARATOR
Intervention: Ranitidine bismuth citrate 400 mg b.d. plus amoxycillin 1 g b.d. and clarithromycin 500 mg b.d. for 10 days (RAC)
Number of subjects: 221

Group type: COMPARATOR
Intervention: Omeprazole 40 mg o.m. plus amoxycillin 1 g b.d. and clarithromycin 500 mg b.d. for 10 days (OAC)
Number of subjects: 221

Group type: COMPARATOR
Intervention: Omeprazole 40 mg o.m. on days 1-5, plus amoxycillin 1 g b.d., clarithromycin 500 mg b.d. and metronidazole 500 mg b.d. on days 3-5 (OACM)
Number of subjects: 221
Study: 8648285

Group type: EXPERIMENTAL
Intervention: Test question asking about the probability of E given C (p(E/C))
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Test question asking about the probability of E given some alternative cause (p(E/C'))
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Test question asking about p(C/E)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Test question asking about p(C/E')
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Conditions where neither causes nor effects competed
Number of subjects: 0
Study: 1728612

Group type: EXPERIMENTAL
Intervention: Group A (patients with intramural metastasis)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional radiotherapy or chemotherapy after surgery
Number of subjects: 60
Study: 6731670

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: 400 mg albendazole with a meal
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: 400 mg albendazole 3 or more hours after or before a meal
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Albendazole (both groups)
Number of subjects: 29
Study: 31941574

Group type: EXPERIMENTAL
Intervention: Resilience-promoting interventions (individual and group formats, more than 12 sessions)
Number of subjects: 2912

Group type: EXPERIMENTAL
Intervention: Interventions based on positive psychology, supportive-expressive group therapy, behavioral therapy, or mindfulness
Number of subjects: 2912
Study: 29481636

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation in children with mild to moderate CKD (ERGO study)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation in children with advanced CKD (4C study)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation in total cohort
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (matched children not receiving vitamin D)
Number of subjects: 80
Study: 27411698

Group type: EXPERIMENTAL
Intervention: Insulin lispro injected into lipohypertrophic tissue (LHT)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Insulin lispro injected into normal adipose tissue (NAT)
Number of subjects: 13
Study: 24676906

Group type: EXPERIMENTAL
Intervention: Autistic subjects
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neurotypical control subjects
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Autistic males
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 0
Study: 22512632

Group type: EXPERIMENTAL
Intervention: Inhaled inactivated Mycobacterium phlei
Number of subjects: 0

Group type: COMPARATOR
Intervention: Salmeterol xinafoate and fluticasone propionate powder (Seretide)
Number of subjects: 0
Study: 20506122

Group type: EXPERIMENTAL
Intervention: Traditional Chinese acupuncture (TCA)
Number of subjects: 455

Group type: EXPERIMENTAL
Intervention: Sham acupuncture
Number of subjects: 455

Group type: COMPARATOR
Intervention: Waiting group
Number of subjects: 455

Group type: EXPERIMENTAL
Intervention: High expectations communication style
Number of subjects: 455

Group type: EXPERIMENTAL
Intervention: Neutral expectations communication style
Number of subjects: 455
Study: 17654188

Group type: EXPERIMENTAL
Intervention: Amniotomy
Number of subjects: 690

Group type: COMPARATOR
Intervention: Intent to conserve membranes
Number of subjects: 690
Study: 16276244

Group type: EXPERIMENTAL
Intervention: Combination drug therapy aimed at raising HDL-cholesterol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Niacin and well-tolerated fibrates as adjunct to statins or primary therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Novel therapeutic approaches
Number of subjects: 0
Study: 11888042

Group type: EXPERIMENTAL
Intervention: Community action interventions including school curricula, parent involvement, peer leadership, and community task forces during Phase 1 (1991-1994) and classroom curriculum, parent education, print media, youth development, and community organizing during Phase 2 (1996-1998).
Number of subjects: 0

Group type: COMPARATOR
Intervention: Minimal intervention during the Interim Phase (1994-1996).
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Annual student surveys, alcohol purchase attempts by young-looking buyers, and parent telephone surveys.
Number of subjects: 0
Study: 9622166

Group type: COMPARATOR
Intervention: modified fetal biophysical profile (mFBP)
Number of subjects: 494

Group type: EXPERIMENTAL
Intervention: external vibratory acoustic stimulation with modified fetal biophysical profile (VAS/mFBP)
Number of subjects: 494

Group type: EXPERIMENTAL
Intervention: VAS/mFBP
Number of subjects: 494
Study: 7619649

Group type: EXPERIMENTAL
Intervention: L-arginine
Number of subjects: 10

Group type: COMPARATOR
Intervention: D-glucose
Number of subjects: 10
Study: 2569309

Group type: EXPERIMENTAL
Intervention: Betaxolol (Kerlone)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Diuretic (xipamide-triamterene combination, Neotri)
Number of subjects: 0
Study: 322649

Group type: EXPERIMENTAL
Intervention: Timolol 0.1%
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Timolol 0.25%
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Timolol 0.5%
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Timolol 1.0%
Number of subjects: 20
Study: 31074532

Group type: EXPERIMENTAL
Intervention: Modified salting-out method
Number of subjects: 0

Group type: COMPARATOR
Intervention: QIAamp® DNA Blood Midi Kit
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Modified QIAamp® DNA Blood Midi Kit
Number of subjects: 0
Study: 28252269

Group type: EXPERIMENTAL
Intervention: Saline infusion sonography (SIS) followed by Pipelle® sampling
Number of subjects: 2

Group type: COMPARATOR
Intervention: Pipelle® sampling followed by saline infusion sonography (SIS)
Number of subjects: 2
Study: 26590673

Group type: EXPERIMENTAL
Intervention: Nintedanib (200 mg twice daily on days 2-21 of every 3-week cycle for up to 120 weeks)
Number of subjects: 1366

Group type: COMPARATOR
Intervention: Placebo (twice daily on days 2-21 of every 3-week cycle for up to 120 weeks)
Number of subjects: 1366

Group type: EXPERIMENTAL
Intervention: Nintedanib
Number of subjects: 1366

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1366
Study: 25082918

Group type: EXPERIMENTAL
Intervention: Moderate-intensity training (MOD group)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: High-intensity training (HIGH group)
Number of subjects: 21
Study: 22338103

Group type: EXPERIMENTAL
Intervention: E/S + extended-release niacin (N; titrated to 2 g)
Number of subjects: 942

Group type: COMPARATOR
Intervention: E/S
Number of subjects: 942